Improving the Pipeline for Developing and Testing Pharmacological Treatments in Pregnancy

PLoS Medicine

Volumn 13, Issue 11, 2016, Pages

  Chappell, Lucy C ^a   David, Anna L ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ATOSIBAN; DIETHYLSTILBESTROL; ERYTHROMYCIN; FOLIC ACID; OXYTOCIN ANTAGONIST; PROCHLORPERAZINE; THALIDOMIDE; DRUG;

ADENOCARCINOMA; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COMORBIDITY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG INDUSTRY; HERBAL MEDICINE; HUMAN; LIMB DEFORMITY; MATERNAL WELFARE; MORBIDITY; MORTALITY; NEURAL TUBE DEFECT; PHARMACODYNAMIC PARAMETERS; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; SELF MEDICATION; TERATOGENICITY; UNLICENSED DRUG USE; FEMALE; METABOLISM; PHARMACOKINETICS;

FEMALE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREGNANCY;

EID: 84999862833     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002161     Document Type: Article

References (13)

1. Ito S, Pariente G, Leibson T, Carls A, Adams-Webber T, Koren G, Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016.
2. Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N, Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proceedings of the National Academy of Sciences of the United States of America. 2009May26;106(21):8573–8. 19433787. Pubmed Central PMCID: 2688998. doi: 10.1073/pnas.0901505106
3. Goodman A, Schorge J, Greene MF, The long-term effects of in utero exposures—the DES story. The New England journal of medicine. 2011Jun2;364(22):2083–4. 21506735. doi: 10.1056/NEJMp1104409
4. Fisk NM, Atun R, Market failure and the poverty of new drugs in maternal health. PLoS Med. 2008Jan22;5(1):e22. 18215109. Pubmed Central PMCID: 2211556. doi: 10.1371/journal.pmed.0050022
5. Glover DD, Amonkar M, Rybeck BF, Tracy TS, Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. American journal of obstetrics and gynecology. 2003Apr;188(4):1039–45. doi: 10.1067/mob.2003.22312712107.
6. Herring C, McManus A, Weeks A, Off-label prescribing during pregnancy in the UK: an analysis of 18,000 prescriptions in Liverpool Women's Hospital. The International journal of pharmacy practice. 2010Aug;18(4):226–9. 20636674. doi: 10.1211/ijpp.18.04.0007
7. van Vliet EO, Boormans EM, de Lange TS, Mol BW, Oudijk MA, Preterm labor: current pharmacotherapy options for tocolysis. Expert opinion on pharmacotherapy. 2014Apr;15(6):787–97. 24533566. doi: 10.1517/14656566.2014.889684
8. UK Teratology Information Service. http://www.uktis.org/ (accessed 8 September 2016)
9. Chambers C, The role of teratology information services in screening for teratogenic exposures: challenges and opportunities. American journal of medical genetics Part C, Seminars in medical genetics. 2011Aug15;157C(3):195–200. 21748849. doi: 10.1002/ajmg.c.30303
10. Godfrey KM, Barker DJ, Fetal programming and adult health. Public health nutrition. 2001Apr;4(2B):611–24. doi: 10.1079/PHN200114511683554.
11. Van Riet-Nales DA, Kozarewicz P, Aylward B, de Vries R, Egberts TC, Rademaker CM, et al. Paediatric Drug Development and Formulation Design-a European Perspective. AAPS PharmSciTech. 2016Jun7. E-pub ahead of print. 27270905. doi: 10.1208/s12249-016-0558-327270905
12. Food U.S. and Drug Administration. Pregnancy and Lactation Labeling (Drugs) Final Rule. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm (accessed 8 September 2016)
13. David AL, Thornton S, Sutcliffe A, Williams P. Developing New Pharmaceutical Treatments for Obstetric Conditions: Scientific Impact Paper No. 50. Royal College of Obstetricians and Gynaecologists, 2015. https://www.rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip-50.pdf